Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
about the author
Endpoints Contributor
help@endpts.com
author articles
Regulatory intelligence: Update on regenerative medicine advanced therapies designations
7 years ago
Cell/Gene Tx
Boosting checkpoint inhibitor efficacy via the microbiome
7 years ago
Whale watching: What a decade of change at Big Pharma taught us about corporate phenotypes
7 years ago
Deals
Biotech Voices
Pharma’s summer of punk: Who's playing the hits — or taking a hit — on the world innovation tour
7 years ago
R&D
Biotech Voices
How the surgical setting contributes to the opioid crisis
7 years ago
Follicum, a Swedish biotech company born to find a treatment for hair loss, now has diabetes in its crosshairs
7 years ago
Pharma, we have a problem: New drugs can't cover the cost of Big Pharma's failures
7 years ago
R&D
Biotech Voices
Celgene's top 20 upfront hits: Just how generous was Celgene in dealmaking? Let's review the records
7 years ago
Pharma
May the candle burn forever: Polite reminders about the JPMorgan confab
7 years ago
Biotech Voices
Aptahem – a Swedish biotech aiming to win the race against sepsis
7 years ago
Focus on targeted value creation and increased strategic management is key to address challenges with R&D ...
7 years ago
Ionis is focused on treating the untreatable with medical breakthroughs for patients
7 years ago
Cereno Scientific is driving a new paradigm of thrombosis prevention without associated bleeding-risks
7 years ago
Novel hepatitis B virus nucleocapsid formation inhibitor CB-HBV-001 demonstrates excellent anti-HBV activity
7 years ago
How trial innovation in Australia is getting therapies to patients sooner
7 years ago
With access to 1.4 billion potential Asia-Pacific trial participants, Novotech CRO can help get your drug to market ...
7 years ago
Guest column: The real cost of drug development
7 years ago
R&D
Biotech Voices
A Swedish biotech is targeting thrombosis using the body's own defense system to prevent blood clots with lower risk ...
7 years ago
The first FDA-approved digital pill — what it means for pharma
7 years ago
Guest column: The 3 big waves reshaping investment strategies in early-stage biotech
7 years ago
Financing
Startups
Is the pharma business model ready for precision medicine?
7 years ago
Biopharmaceutical Dealmakers’ Intentions in 2018: Supply and Demand Expectations and Imbalances
7 years ago
Swedish Biotech DexTech Medical shoots for billion dollar prostate cancer market — concludes phIIb study early
7 years ago
Biopharmaceutical Dealmakers’ Intentions in 2018: Bullish Run to Continue Amidst Signs of Greater Risk Aversion
7 years ago
First page
Previous page
8
9
10
11
12
Next page
Last page